Treatment with DPP-4 inhibitors does not increase the chance of pancreatitis in patients with type 2 diabetes.
OBJECTIVES: This retrospective analysis was done in type 2 diabetes patients to study whether treatment with either sitagliptin or other Dipeptidyl peptidase-4 (DPP-4) inhibitors increased the risk of pancreatitis. Comparison with patients treated with ot.....